{
  "abstract": "Introduction: Trastuzumab deruxtecan (T-DXd) has been approved for the second-line therapy of human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer, revolutionizing the treatment landscape for this clinical scenario.\n\nCase Presentation: Given the lack of real-world evidence, here we reported a patient with HER2-positive, metastatic gastroesophageal junction adenocarcinoma treated with T-DXd in the second-line setting. The patient, a 63-year-old male, previously received first-line treatment with trastuzumab plus oxaliplatin, capecitabine and sintilimab but disease progression occurred at 4.5 months. He subsequently received T-DXd-based therapy for a total of 22 treatment cycles and achieved a progression-free survival (PFS) of 23 months, with improved performance status and no T-DXd treatment dose reduction during treatment.\n\nConclusion: This case firstly supplements the real-world data of T-DXd for patients with HER2-positive advanced gastric cancer in the second-line setting. These data indicate the PFS benefit with second-line T-DXd-based treatment even after rapid progression on trastuzumab-based therapy and the safety of full-dose T-DXd during long-course treatment.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Oncology, Chinese PLA General Hospital, The Fifth Medical Center",
    "Department of Oncology, Chinese PLA General Hospital, The First Medical Center"
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 4,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Yuanmei Dong"
    },
    {
      "affs": [
        1
      ],
      "name": "Li Zhang"
    },
    {
      "affs": [
        1
      ],
      "name": "Lan Zhao"
    },
    {
      "affs": [
        0
      ],
      "name": "Yanyun Zhu"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/ekmymvbk379cv.bib",
  "cited_by": 0,
  "doi": "10.3389/fphar.2026.1913044",
  "fulltext_url": null,
  "id": "ekmymvbk379cv",
  "issns": [
    "1663-9812"
  ],
  "landing_url": "https://www.frontiersin.org/articles/10.3389/fphar.2026.1913044/full",
  "language": null,
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [],
  "openalex": null,
  "pdf_url": null,
  "pmcid": null,
  "pmid": null,
  "published": "2026-11-04",
  "publisher": "Frontiers Media SA",
  "ris": "https://research.draconitic.com/paper/ekmymvbk379cv.ris",
  "sources": [
    {
      "first_seen": "2026-11-04T12:21:43Z",
      "native_id": "10.3389/fphar.2026.1913044",
      "source": "crossref",
      "url": "https://www.frontiersin.org/articles/10.3389/fphar.2026.1913044/full"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "issn:1663-9812",
      "subfield": "pharmacology-toxicology"
    }
  ],
  "title": "Progression-free survival of 23 months with second-line trastuzumab deruxtecan in HER2-positive gastroesophageal junction adenocarcinoma: a case report",
  "title_text": "Progression-free survival of 23 months with second-line trastuzumab deruxtecan in HER2-positive gastroesophageal junction adenocarcinoma: a case report",
  "type": "peer-reviewed",
  "updated_at": "2026-11-06T00:21:25Z",
  "url": "https://research.draconitic.com/paper/ekmymvbk379cv",
  "venue": "Frontiers in Pharmacology",
  "versions": []
}